<!DOCTYPE html>
<html lang="en">

<head>
  <title>Anticonvulsants | The Peripheral Brain</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.2/MathJax.js?config=TeX-MML-AM_CHTML'></script>
  <script src="/peripheral_brain/javascript/mermaid.min.js"></script>

  <link rel="stylesheet" href="/peripheral_brain/css/main.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/mobile.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/buttons.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/mermaid.dark.css" />

  
    <link rel="stylesheet" href="/peripheral_brain/css/diseases.css">
  


  <link href="https://fonts.googleapis.com/css?family=Open+Sans" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Slab" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Mono" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Condensed" rel="stylesheet">


  <link rel="apple-touch-icon" sizes="180x180" href="/peripheral_brain/favicons/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/peripheral_brain/favicons/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/peripheral_brain/favicons/favicon-16x16.png">
  <link rel="manifest" href="/peripheral_brain/favicons/site.webmanifest">
  <link rel="mask-icon" href="/peripheral_brain/favicons/safari-pinned-tab.svg" color="#465c8b">
  <link rel="shortcut icon" href="/peripheral_brain/favicons/favicon.ico">
  <meta name="apple-mobile-web-app-title" content="Peripheral Brain">
  <meta name="application-name" content="Peripheral Brain">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/peripheral_brain/favicons/browserconfig.xml">
  <meta name="theme-color" content="#cdcdcd">


  

</head>


<body class="body">
<header id="myHeader" class="myHeader">
  <nav>
    <!-- <a href="/peripheral_brain/home.html"><img src="/peripheral_brain/images/logo_1000x1000.png" alt="Logo"> -->
    <a href="/peripheral_brain/home.html">Home</a>
    <a href="/peripheral_brain/disease_list.html">Diseases and Drugs</a>
    <a href="/peripheral_brain/firstFive">TF5M</a>
    <a href="/peripheral_brain/lab_values">Lab Values</a>
    <a href="/peripheral_brain/formulas">Formulas</a>
    <a href="/peripheral_brain/calculators.html">Calculators</a>
    <a href="/peripheral_brain/search.html">Search</a>
    <a href="javascript:void(0);" class="icon" onclick="openMenu()">&#9776;</a>
  </nav>

  <script>
  function openMenu() {
      var x = document.getElementById("myHeader");
      if (x.className === "myHeader") {
          x.className += " responsive";
      } else {
          x.className = "myHeader";
      }
  }
  </script>
</header>


<h1 class="title">Anticonvulsants</h1>

<div class="contents twoCol">
  <div class="toc col1">
    
      <ul>
  <li><a href="#anticonvulsant-classifications">Anticonvulsant Classifications</a></li>
  <li><a href="#na-channel-mediated-moa">Na Channel Mediated MOA</a>
    <ul>
      <li><a href="#hydantoin-derivatives-phenytoin-etc">Hydantoin Derivatives (Phenytoin, etc.)</a></li>
      <li><a href="#iminostilbenes-carbamazepine-etc">Iminostilbenes (Carbamazepine, etc.)</a></li>
      <li><a href="#lacosamide">Lacosamide</a></li>
    </ul>
  </li>
  <li><a href="#ca-channel-inhibitors">Ca Channel Inhibitors</a>
    <ul>
      <li><a href="#clinical-uses">Clinical Uses</a></li>
      <li><a href="#succinimides">Succinimides</a></li>
      <li><a href="#example-drugs-2">Example Drugs</a></li>
    </ul>
  </li>
  <li><a href="#mixed-na-and-ca-inhibitors">Mixed Na and Ca Inhibitors</a>
    <ul>
      <li><a href="#lamotrigine-lamictal">Lamotrigine (Lamictal)</a></li>
      <li><a href="#valproate-depaken-depakote">Valproate (Depaken, Depakote)</a></li>
    </ul>
  </li>
  <li><a href="#gabaergic-drugs">GABAergic Drugs</a>
    <ul>
      <li><a href="#barbiturates">Barbiturates</a></li>
      <li><a href="#benzodiazepines">Benzodiazepines</a></li>
      <li><a href="#gaba-analogs">GABA Analogs</a></li>
      <li><a href="#vigabatrin-sabrile">Vigabatrin (Sabrile)</a></li>
      <li><a href="#tiagabine-gabatril">Tiagabine (Gabatril)</a></li>
    </ul>
  </li>
  <li><a href="#glutamate-antagonists">Glutamate Antagonists</a>
    <ul>
      <li><a href="#felbamate-felbatol">Felbamate (Felbatol)</a></li>
      <li><a href="#topiramate">Topiramate</a></li>
    </ul>
  </li>
  <li><a href="#misc-anticonvulsants">Misc Anticonvulsants</a>
    <ul>
      <li><a href="#levetiracetam-keppra">Levetiracetam (Keppra)</a></li>
      <li><a href="#brivaracetam-briviact">Brivaracetam (Briviact)</a></li>
    </ul>
  </li>
</ul>

    
  </div>

  <div class="content col2">
    <h1 id="anticonvulsant-classifications">Anticonvulsant Classifications</h1>

<ul>
  <li>Decreased Na influx and prolonged Na Channel Inactivation
    <ul>
      <li>Carbamazepine (Tegretol)</li>
      <li>Oxcarbazepine (Trileptal)</li>
      <li>Phenytoin (Dilantin)</li>
      <li>Lacosamide (Vimpat)</li>
      <li>Lamotrigine</li>
      <li>Valproate</li>
    </ul>
  </li>
  <li>Reduction of Ca Influx
    <ul>
      <li>Ethosuximide</li>
      <li>Lamotrigine</li>
      <li>Valproate</li>
    </ul>
  </li>
  <li>Enhanced GABA-mediated Inhibition
    <ul>
      <li>Barbiturates (GABA<sub>A</sub> agonist)</li>
      <li>Benzodiazepines (GABA<sub>A</sub> agonist)</li>
      <li>Valproate (Increases GABA Levels)</li>
      <li>Gabapentin (Increases GABA Levels)</li>
      <li>Vigabatrin (Inhibits GABA Transaminase)</li>
      <li>Tiagabine (Inhibits GAT-1)</li>
    </ul>
  </li>
  <li>Antagonism of Glutamate and Other Excitatory Neurotransmitters
    <ul>
      <li>Felbamate (NMDA Antagonist)</li>
      <li>Topiramate (Kainate / AMPA Antagonist)</li>
    </ul>
  </li>
</ul>

<h1 id="na-channel-mediated-moa">Na Channel Mediated MOA</h1>

<h2 id="hydantoin-derivatives-phenytoin-etc">Hydantoin Derivatives (Phenytoin, etc.)</h2>

<h3 id="moa">MOA</h3>

<p>Binds and stabilizes the inactivated state of Na Channels</p>

<h3 id="example-drugs">Example Drugs</h3>

<ul>
  <li>Phenytoin</li>
  <li>Fosphenytoin</li>
  <li>Ethotoin (fewer SEs than phenytoin, but less effective)</li>
  <li>Mephenytoin (more toxic than phenytoin)</li>
</ul>

<h3 id="phenytoin">Phenytoin</h3>

<p>Phenytoin has unique PK properties, as the metabolic enzymes which control phenytoin metabolism are saturated at therapeutic concentrations. This leads to non-linear pharmacokinetics. Phenytoin is also highly protein bound, and induces CYP enzymes leading to a large number of drug interactions</p>

<h2 id="iminostilbenes-carbamazepine-etc">Iminostilbenes (Carbamazepine, etc.)</h2>

<h3 id="moa-1">MOA</h3>

<p>Iminostilbenes bind and stabilize the incativated state of Na channels in the brain in a similar way to hydantoins (their 3D structures are very similar); however their planar structures are tricyclic. Iminostilbenes induce hepatic CYPs leading to many drug interactions</p>

<h3 id="example-drugs-1">Example Drugs</h3>

<ul>
  <li>Carbamazepine</li>
  <li>Oxcarbazepine</li>
</ul>

<h2 id="lacosamide">Lacosamide</h2>

<h3 id="moa-2">MOA</h3>

<p>Enhances the inactivation of Na channels</p>

<h1 id="ca-channel-inhibitors">Ca Channel Inhibitors</h1>

<h2 id="clinical-uses">Clinical Uses</h2>

<p>Absence Szs only</p>

<h2 id="succinimides">Succinimides</h2>

<h3 id="moa-3">MOA</h3>

<p>Inhibition of T-Type Ca Channels in thalamic neurons</p>

<h2 id="example-drugs-2">Example Drugs</h2>

<ul>
  <li>Ethosuximide (Zarontin)</li>
  <li>Methsuximide (more toxic)</li>
  <li>Phensuximide (less effective)</li>
</ul>

<h1 id="mixed-na-and-ca-inhibitors">Mixed Na and Ca Inhibitors</h1>

<h2 id="lamotrigine-lamictal">Lamotrigine (Lamictal)</h2>

<h3 id="moa-4">MOA</h3>

<p>Inhibition of Ca and Na channels (has effects of both classes, and can therefore be used for more than absence Szs). Also disrupts glutamate release</p>

<h2 id="valproate-depaken-depakote">Valproate (Depaken, Depakote)</h2>

<h3 id="moa-5">MOA</h3>

<p>Inhibition of Ca and Na channels (has effects of both classes, and can therefore be used for more than absence Szs). Increases GABA levels by stimulating glutamic acid decarboxylase or inhibiting GAt-1 or GABA-T</p>

<h1 id="gabaergic-drugs">GABAergic Drugs</h1>

<h2 id="barbiturates">Barbiturates</h2>

<h3 id="moa-6">MOA</h3>

<p>PAM of GABA<sub>A</sub> receptors increasing the <strong>duration</strong> of Cl entry into the post-synaptic neuron (an inhibitory signal). At high concentrations these drugs can also inhibit Na and Ca channels. Primidone may have more similar behaviors to phenytoin.</p>

<h3 id="example-drugs-3">Example Drugs</h3>

<ul>
  <li>Phenobarbital (Luminal)</li>
  <li>Primidone (Mysoline)</li>
</ul>

<h2 id="benzodiazepines">Benzodiazepines</h2>

<h3 id="moa-7">MOA</h3>

<p>PAM of GABA<sub>A</sub> receptors increasing the <strong>frequency</strong> of Cl opening events, hyperpolarizing the post-synaptic neuron.</p>

<h3 id="example-drugs-4">Example Drugs</h3>

<ul>
  <li>Diazepam (Valium)</li>
  <li>Lorazepam (Ativan)</li>
  <li>Clonazepam (Klonopin)</li>
</ul>

<h2 id="gaba-analogs">GABA Analogs</h2>

<h3 id="moa-8">MOA</h3>

<p>Increases GABA release and potentially decreases presynaptic Ca influx reducing glutamate release.</p>

<h3 id="example-drugs-5">Example Drugs</h3>

<ul>
  <li>Gabapentin (Neurontin)</li>
  <li>Pregabalin (Lyrica)</li>
</ul>

<h2 id="vigabatrin-sabrile">Vigabatrin (Sabrile)</h2>

<h3 id="moa-9">MOA</h3>

<p>Analog of GABA which irreversibly inhibits GABA transaminase, which normally degrades GABA. Mat also inhibit GAT.</p>

<h2 id="tiagabine-gabatril">Tiagabine (Gabatril)</h2>

<h3 id="moa-10">MOA</h3>

<p>Inhibits GAT-1 (GABA vesicular transporter)</p>

<h1 id="glutamate-antagonists">Glutamate Antagonists</h1>

<h2 id="felbamate-felbatol">Felbamate (Felbatol)</h2>

<h3 id="moa-11">MOA</h3>

<p>NMDA Antagonist (NMDA Usually triggers influx of Na and Ca, along with Efflux of K) and enhanced GABA<sub>A</sub> signaling.</p>

<h2 id="topiramate">Topiramate</h2>

<h3 id="moa-12">MOA</h3>

<p>AMPA (Na influx and K efflux) and Kainate antagonist. Inhibition of Na Channels. Enhanced GABA<sub>A</sub> signaling.</p>

<h1 id="misc-anticonvulsants">Misc Anticonvulsants</h1>

<h2 id="levetiracetam-keppra">Levetiracetam (Keppra)</h2>

<h3 id="moa-13">MOA</h3>

<p>Binds SV<sub>2</sub>A (Synaptic Vesicular Protein) interfering with neurotransmitter release. May also interfere with Ca influx in presynaptic neurons</p>

<h2 id="brivaracetam-briviact">Brivaracetam (Briviact)</h2>

<h3 id="moa-14">MOA</h3>

<p>Analog of levetiracetem with higher affinity for SV<sub>2</sub>A</p>

  </div>

</div>

<div class="credits">
  <p>Author: Corbin Cox <br>
  Created: 2018-3-19 <br>
  Last Updated: 2018-3-24</p>
</div>

<footer class="footer menus">
  <nav>
    <div class="footerLinks">
      <a href="/peripheral_brain/home.html">Home</a>
      <a href="/peripheral_brain/index.html">Disclaimer</a>
      <a href="/peripheral_brain/disease_list_old.html">Archived Diseases</a>
    </div>
  </nav>
</footer>


</body>
</html>
